Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
J Med Chem ; 36(22): 3381-5, 1993 Oct 29.
Article in English | MEDLINE | ID: mdl-8230128

ABSTRACT

Title compound, 8, has been synthesized from isoquinolinone, 1 (an improved preparation for which is presented) and separated into its antipodes with D- and L-di-p-toluoyltartaric acids. These antipodes and the racemic precursor have been evaluated (and found active) in two in vivo systems for their effects. The most potent of the three, (+)-8, has an ED50 of 7.13 mumol/kg for inhibition of spontaneous activity and 7.45 mumol/kg for antinociception compared to 4.44 and 4.81 mumol/kg, respectively, for (S)-(-)-nicotine. Compounds (-)-8 and 7 are about one-fourth as potent. Isomer (+)-8 has the 3aR,9bS configuration, the latter corresponding to (S)-(-)-nicotine as determined by X-ray crystallography. However, (+)-8 failed to compete for [3H]-nicotine binding, and its pharmacological effects were not blocked by mecamylamine. These bridged nicotine analogs either are binding to an as-yet-unidentified nicotinic receptor or they represent a novel class of non-nicotinic analgesics.


Subject(s)
Ganglionic Stimulants/chemical synthesis , Ganglionic Stimulants/pharmacology , Isoquinolines/chemical synthesis , Isoquinolines/pharmacology , Nicotine/analogs & derivatives , Analgesics/chemical synthesis , Animals , Behavior, Animal/drug effects , Depression, Chemical , Ganglionic Stimulants/metabolism , Isoquinolines/metabolism , Kinetics , Mice , Molecular Conformation , Molecular Structure , Nicotine/chemical synthesis , Nicotine/metabolism , Nicotine/pharmacology , Nicotinic Antagonists , Nociceptors/drug effects , Receptors, Nicotinic/physiology , Stereoisomerism , X-Ray Diffraction
2.
J Med Chem ; 34(3): 1003-10, 1991 Mar.
Article in English | MEDLINE | ID: mdl-2002445

ABSTRACT

Nine analogues of mecamylamine (2) which differ in the number and substitution pattern of methyl groups, were prepared. In four of these analogues the amine functionality is in an endo orientation. Enantiomers of 2-endo- and 2-exo-N-methylfenchylamine (25 and 26, respectively) were also prepared. The hydrochloride salts of these compounds were tested for nicotinic antagonism relative to mecamylamine in vivo and none was found to be as potent as mecamylamine, although a broad range of activity was observed. In general, methyl substituents at the C1, C2, and C7 positions of the mecamylamine structure do not appear to be significant for antagonistic activity. Methyl substituents at C3, however, appear to be very important for activity. Three sets of enantiomers of N-methylfenchylamine analogues, 28-30, possessing structural features of mecamylamine and nicotine were also prepared. These compounds were inactive as antagonists. Only a small degree of stereoselectivity was elicited in this series, less than that seen with enantiomers of nicotine. Antagonists with the exo N-methylamine functionality are slightly more active than the endo isomers. The extent to which structural modification might change lipophilicities was estimated through calculated partition coefficients; such changes alone appeared insufficient to explain differences in activities of the analogues. Lastly, a tolerance for a tertiary (dimethyl) amine functionality was demonstrated in addition to the lack of tolerance for bulkier substituents at C3 or on the nitrogen.


Subject(s)
Mecamylamine/analogs & derivatives , Nicotine/antagonists & inhibitors , Analgesia , Animals , Chemical Phenomena , Chemistry , Mecamylamine/chemical synthesis , Mecamylamine/pharmacology , Mice , Molecular Structure , Motor Activity/drug effects , Stereoisomerism , Structure-Activity Relationship
3.
J Pharmacol Exp Ther ; 254(1): 45-51, 1990 Jul.
Article in English | MEDLINE | ID: mdl-2366189

ABSTRACT

The nature of mecamylamine's and pempidine's antagonism of nicotine in the central nervous system has not been defined clearly. Although these compounds are thought to be noncompetitive antagonists in the brain due to the fact that they do not compete effectively for agonist binding to brain tissue in vitro, pharmacological evidence is lacking. The alteration of nicotine's dose-response curves for depression of spontaneous activity and antinociception was determined in the presence of increasing concentrations of pempidine. Pempidine was found to increase the ED50 of nicotine (0.73 mg/kg) for depression of spontaneous activity in a dose-related manner. At a dose of 3 mg/kg, pempidine increased nicotine's ED50 4.7-fold. The maximum effect of nicotine was achieved in the presence of the highest dose of pempidine, suggesting competitive antagonism. However, pempidine did decrease the maximum effect of nicotine in producing antinociception at doses that increased the ED50 13.7-fold which suggests a noncompetitive action. The structural requirements for mecamylamine's antagonism of these nicotine effects was also determined in order to address the question of whether the antagonists are interacting at a receptor site. The structure-activity relationships of the mecamylamine analogs revealed that the N-, 2- and 3-methyl groups were important for optimal potency. Optical isomerism was found to have little effect on potency. Addition of pyridinyl groups to the nitrogen abolished the activity of these compounds. The structural requirements for the agonists and antagonists therefore appear to be quite different. The alterations produced similar results for antagonism of both effects of nicotine. Mecamylamine and pempidine therefore appear to exhibit both competitive and noncompetitive properties in antagonizing the central effects of nicotine.


Subject(s)
Brain/drug effects , Mecamylamine/pharmacology , Nicotine/antagonists & inhibitors , Pempidine/pharmacology , Analgesia , Animals , Dose-Response Relationship, Drug , Male , Mice , Mice, Inbred ICR , Motor Activity/drug effects , Stereoisomerism , Structure-Activity Relationship
6.
J Pharm Sci ; 76(9): 738-43, 1987 Sep.
Article in English | MEDLINE | ID: mdl-11002812

ABSTRACT

Analysis of outdated clinical samples of maytansine formulated in mannitol indicated that approximately 40% of the original maytansine content had decomposed. Chromatographic examination of these samples showed the presence of one major and multiple minor decomposition products. The major decomposition product was found to be maysine, a naturally occurring maytansinoid resulting from hydrolytic elimination of the C-3 ester side chain. Four minor decomposition products were isolated with the use of HPLC. All of these decomposition products were found to possess the C-3 ester side chain. However, other structural modifications were noted, especially in the region of the C-9 carbinolamide. Two of the minor decomposition products were tentatively identified as 10-epimaytansine and 9-epimaytansine. One minor decomposition product was found to contain a hydroxyl group at the benzylic C-15 position.


Subject(s)
Antineoplastic Agents, Phytogenic/chemistry , Maytansine/chemistry , Magnetic Resonance Spectroscopy , Mass Spectrometry
SELECTION OF CITATIONS
SEARCH DETAIL
...